ReviewJournal of ophthalmic & vision research2024
Recent Nanotechnological Trends in the Management of Microbial Keratitis.
Review in Journal of ophthalmic & vision research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biofilm Formation and Antibiotic Susceptibility Patterns in Contact Lens-Associated Bacteria.Korean journal of ophthalmology : KJO · 2026Article
- Advances in the molecular pathogenesis ofFrontiers in cellular and infection microbiology · 2026Review
- Invasomes and Nanostructured Lipid Carriers for Targeted Delivery of Ceftazidime Combined with N-Acetylcysteine: A Novel Approach to TreatPharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial keratitis (MK) is a sight-threatening ocular disease that needs rapid diagnosis and treatment to prevent more serious outcomes. The broad-spectrum topical antimicrobial treatment is currently the main pharmacological approach for MK management, yet its efficacy is increasingly challenged by evolving antimicrobial resistance, including multidrug resistance. Also, the ocular surface presents numerous challenges for standard topical drug delivery. The failure and ineffectiveness of current therapies have necessitated the development of novel therapeutic strategies to manage MK. With advances in nanotechnology in the biomedical field, various nanomaterials can be employed to control MK. The primary determinants of nanoparticles' vast range of applications are their size, surface properties, and chemical makeup, which also happen to be the same elements that give rise to their poisonous and dangerous effects. In this study, we provide a perspective on the contact lens-associated corneal illnesses such as MK and explore how nanotechnology might help address this significant clinical issue. In addition, safety and toxicological concerns about the increasingly widespread use of contact lenses are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.